Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 12/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1680203 | 1.00 | PDE5A (0.60) | PDE5A | |
| SCHEMBL5629173 | 0.88 | PDE5A (0.56) | PDE5A | |
| SCHEMBL14514212 | 0.87 | PDE5A (0.62) | PDE5A | |
| SCHEMBL1679526 | 0.86 | PDE5A (0.81) | PDE5A | |
| SCHEMBL1679528 | 0.86 | PDE5A (0.81) | PDE5A | |
| SCHEMBL1679815 | 0.86 | PDE5A (0.75) | PDE5A | |
| SCHEMBL1679812 | 0.86 | PDE5A (0.75) | PDE5A | |
| SCHEMBL4977132 | 0.85 | PDE5A (0.61) | PDE5A | |
| SCHEMBL4977144 | 0.85 | PDE5A (0.61) | PDE5A | |
| SCHEMBL5248876 | 0.85 | PDE5A (0.61) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179701-A1 | COMPOSITION FOR REDUCING SKIN WRINKLES INCLUDING PDE5 INHIBITOR | SK CHEMICALS CO., LTD. (KR) | 2014-06-26 | — | — | US | claimed |
| EP-2556820-A2 | COMPOSITION CONTAINING PDE5 INHIBITOR FOR RELIEVING SKIN WRINKLES | SK Chemicals, Co., Ltd. (KR) | 2013-02-13 | — | — | EP | claimed |
| US-20130030174-A1 | COMPOSITION FOR REDUCING SKIN WRINKLES INCLUDING PDE5 INHIBITOR | SK CHEMICALS CO., LTD. (KR) | 2013-01-31 | — | — | US | claimed |
| EP-1366760-B1 | TABLETS QUICKLY DISINTEGRATED IN ORAL CAVITY | MITSUBISHI TANABE PHARMA CORP (JP) | 2010-06-30 | — | — | EP | claimed |
| EP-1219609-B1 | AROMATIC NITROGENOUS SIX-MEMBERED RING COMPOUNDS | TANABE SEIYAKU CO (JP) | 2007-04-04 | — | — | EP | claimed |
| US-6797709-B2 | SEXUAL DISORDERS | TANABE SEIYAKU CO., LTD. (JP) | 2004-09-28 | — | — | US | claimed |
| CN-1527701-A | Tablets quickly disintegrated in oral cavity | ������ҩ��ʽ���� | 2004-09-08 | — | — | CN | claimed |
| US-20040109890-A1 | Tablets quickly disintegrated in oral cavity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-06-10 | — | — | US | claimed |
| US-20030229095-A1 | Sexual disorders | TANABE SEIYAKU CO., LTD. | 2003-12-11 | — | — | US | claimed |
| EP-1366760-A1 | TABLETS QUICKLY DISINTEGRATED IN ORAL CAVITY | TANABE SEIYAKU CO., LTD. (JP) | 2003-12-03 | — | — | EP | claimed |
| US-20030032647-A1 | Treatment of penile erectile dysfunction, pulmonary hypertension, and diabetic gastroparesis | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2003-02-13 | — | — | US | claimed |
| EP-1219609-A1 | AROMATIC NITROGENOUS SIX-MEMBERED RING COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2002-07-03 | — | — | EP | claimed |
| US-9155691-B2 | Composition for reducing skin wrinkles including PDE5 inhibitor | SK CHEMICALS CO., LTD. (KR) | 2015-10-13 | — | — | US | disclosed |
| US-20140179701-A1 | COMPOSITION FOR REDUCING SKIN WRINKLES INCLUDING PDE5 INHIBITOR | SK CHEMICALS CO., LTD. (KR) | 2014-06-26 | — | — | US | disclosed |
| US-8716298-B2 | Composition for reducing skin wrinkles including PDE5 inhibitor | SK CHEMICALS CO., LTD. (KR) | 2014-05-06 | — | — | US | disclosed |
| CN-102970965-A | Composition containing PDE5 inhibitor for relieving skin wrinkles | SK CHEMICALS CO LTD | 2013-03-13 | — | — | CN | disclosed |
| EP-1366760-A1 | TABLETS QUICKLY DISINTEGRATED IN ORAL CAVITY | TANABE SEIYAKU CO., LTD. (JP) | 2003-12-03 | — | — | EP | disclosed |
| US-6656935-B2 | Treatment of penile erectile dysfunction, pulmonary hypertension, and diabetic gastroparesis | TANABE SEIYAKU CO., LTD. (JP) | 2003-12-02 | — | — | US | disclosed |
| US-20030032647-A1 | Treatment of penile erectile dysfunction, pulmonary hypertension, and diabetic gastroparesis | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2003-02-13 | — | — | US | disclosed |
| EP-1219609-A1 | AROMATIC NITROGENOUS SIX-MEMBERED RING COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032647-A1 | Treatment of penile erectile dysfunction, pulmonary hypertension, and diabetic gastroparesis | PDE3A, PDE3B, PDE2A | PDE5A 4/4885 |
| US-20030229095-A1 | Sexual disorders | PDE3B, PDE3A, PDE2A | PDE5A 4/4885 |
| US-20040109890-A1 | Tablets quickly disintegrated in oral cavity | SI, TAS2R60, TAS2R30 | PDE5A 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.